Journal Browser

Journal Browser

Special Issue "Current Advances in Soft Tissue and Bone Sarcoma 2.0"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (28 February 2020).

Special Issue Editors

Prof. Dr. Shunji Takahashi
E-Mail Website
Guest Editor
1: Department of Oncotherapeutic Medicine, Graduate School of Medicine, Tohoku University, Sendai, Japan
2: Department of Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan
Interests: new antineoplastic drugs; resistance to molecular target drug; biomarkers of cancer; bone metastases of cancer; sarcomas
Prof. Dr. Eugenie S. Kleinerman
E-Mail Website
Guest Editor
University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
Interests: medicine and surgery; cell biology; osteosarcoma
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,


We are pleased to announced the continuation of our Special Issue “Current Advances in Soft Tissue and Bone Sarcoma” with a second edition.


The molecular basis of soft tissue and bone sarcoma has received considerable attention during the last decade. However, clinical outcomes continue to be dismal and have landed this group of cancers among the “most pressing” for development of new, effective therapies. The main barrier to successfully treating many sarcoma types is the lack of robust prognostic markers and the absence of effective therapeutics. The complex biology and tumor heterogeneity of sarcomas make it challenging to identify and evaluate new therapeutic targets and agents. These challenges are also compounded by the orphan disease status.


In this Special Issue, original studies and review articles on the diagnosis, pathobiology, and novel therapies of soft tissue and bone sarcoma, including genetics, epigenetics, immunotherapies, epidemiology, signaling pathways, and preclinical models, will be published. The issue will also cover reports on current treatments and novel combination therapies, including immunotherapies, providing novel mechanistic insights that may impact clinical outcomes.


Prof. Dr. Shunji Takahashi
Prof. Dr. Eugenie S. Kleinerman
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Soft tissue sarcoma
  • Osteosarcoma
  • Pathobiology
  • Genetics
  • Current treatments
  • Diagnosis
  • Outcomes and preclinical models

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Open AccessArticle
Cold Atmospheric Plasma Treatment of Chondrosarcoma Cells Affects Proliferation and Cell Membrane Permeability
Int. J. Mol. Sci. 2020, 21(7), 2291; https://doi.org/10.3390/ijms21072291 (registering DOI) - 26 Mar 2020
Chondrosarcoma is the second most common malign bone tumor in adults. Surgical resection of the tumor is recommended because of its resistance to clinical treatment such as chemotherapy and radiation therapy. Thus, the prognosis for patients mainly depends on sufficient surgical resection. Due [...] Read more.
Chondrosarcoma is the second most common malign bone tumor in adults. Surgical resection of the tumor is recommended because of its resistance to clinical treatment such as chemotherapy and radiation therapy. Thus, the prognosis for patients mainly depends on sufficient surgical resection. Due to this, research on alternative therapies is needed. Cold atmospheric plasma (CAP) is an ionized gas that contains various reactive species. Previous studies have shown an anti-oncogenic potential of CAP on different cancer cell types. The current study examined the effects of treatment with CAP on two chondrosarcoma cell lines (CAL-78, SW1353). Through proliferation assay, the cell growth after CAP-treatment was determined. A strong antiproliferative effect for both cell lines was detected. By fluorescein diacetate (FDA) assay and ATP release assay, alterations in the cell membrane and associated translocation of low molecular weight particles through the cytoplasmic membrane were observed. In supernatant, the non-membrane-permeable FDA and endogenously synthesized ATP detected suggest an increased membrane permeability after CAP treatment. Similar results were shown by the dextran-uptake assay. Furthermore, fluorescence microscopic G-/F-actin assay was performed. G- and F-actin were selectively dyed, and the ratio was measured. The presented results indicate CAP-induced changes in cell membrane function and possible alterations in actin-cytoskeleton, which may contribute to the antiproliferative effects of CAP. Full article
(This article belongs to the Special Issue Current Advances in Soft Tissue and Bone Sarcoma 2.0)
Back to TopTop